Endocrine Abstracts

In the last years an increasing incidence of cardiovascular diseases (CVD) has been reported in young adults (18-45 yrs), probably accounted by the significant increase in CV risk (CVR) factors. Observational and interventional studies, mainly focused on middle-aged and elderly men, demonstrated that metabolic CVR (mCVR) factors and CVD manifestations are common in hypogonadal men and, conversely, testosterone deficiency is highly prevalent in metabolic disorders; the lack of ...

Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularities and clinical and biochemical hyperandrogenism, and is associated with insulin resistance, visceral obesity and metabolic disorders. The aim of the current study was to compare the effects of inositol isomers (INO) and metformin (MET) on the clinical, metabolic and hormonal aspects of PCOS. In 94 PCOS women, clinical (weight, BMI, waist circumference - WC, menstrual intervals, Ferriman-Gallway score -...

Obesity, characterized by an abnormal body fat accumulation mainly caused by a chronic imbalance between energy intake and expenditure, is a massive public health problem. Targeting excessive fat deposition in adipose tissue and ectopic fat accumulation in skeletal muscle through promoting lipid oxidation pathway may represent a promising strategy to counteract obesity. This study aims at investigating the effects of cabergoline (CAB), a dopamine agonist, on adipose and skelet...

Prolactin (PRL) exerts independent hypertrophic effects on prostate in in vivo and in vitro experimental models, and prostatic PRL receptors are known to activate cell proliferation pathways such as MAPK and STAT. Nevertheless, in men with hyperprolactinemia the risk of prostate cancer has been found reduced suggesting a role of concomitant hypogonadism. Chronic cabergoline treatment generally normalizes PRL treatment and improves gonadal function. The curren...

Cushing’s Syndrome (CS) is associated with a severe myopathy mainly affecting type 2 muscle fibres, with a higher prevalence in male subjects. The excess of glucocorticoids (GC) levels represents the most common cause of myopathy due to an alteration of protein metabolism. The non-coding post-transcriptional gene regulators muscle-specific microRNAs (miRNA) control muscle development and differentiation but when dysregulated lead to skeletal muscle (SM) disorder. The aim ...

HCC is a difficult-to-treat- cancer with poor prognosis. Despite EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced sorafenib resistant HCC, in selected patients, the established antitumor effect of EVE could make this drug a potential adjuvant therapy. Unfortunately, the acquired EVE resistance due to the tumour adaptation to chronic drug use is a current challenge. VitD has been deemed as pote...

Introduction: Environmental toxins, including those deriving from illegal and hazardous disposal of urban and chemical waste, are known to act as endocrine disruptors and to increase the risk of malignancy and cancer mortality. The present study aimed at investigating prevalence and characteristics of thyroid diseases in the area of Acerra, a town in the perimeter of the so called ‘Land of Fires’.Methods: The screening included subjects aged &#...

Ovarian cancer (OC) is the most lethal gynecological cancer. Debulking surgery and platinum-based chemotherapy are the cornerstone of OC management; however, after a partial initial response, tumors invariably relapse. Therapeutic approaches should account for interindividual heterogeneity since OC histiotypes show distinct genetic profile. A2780 cell line has been annotated as high grade serous ovarian cancer (HGSOC); nevertheless, recent research underlined that the genetic ...

HCC is one of the most common malignancies worldwide. Local approaches are generally preferred for patients whose disease is restricted to the liver. In patients with extrahepatic disease systemic therapy can be considered. Chemotherapy did not demonstrate convincing survival advantages in several trails for HCC patients. Presently, the kinase inhibitor sorafenib is the only approved systemic target therapy for the treatment of advanced HCC. Mitotane (dichlorodiphenildichloroe...

HCC is a difficult-to-treat- cancer with poor prognosis. The recent EVOLVE-1 trial demonstrated that EVE did not improve overall survival in molecularly and clinically unselected patients with advanced HCC resistant to sorafenib treatment. In selected patients, the well-established antitumor effect of EVE could make this drug a potential adjuvant therapy. Unfortunately, the acquired resistance to this molecule due to the tumor adaptation to chronic drug use is a current challe...